CN101594778A - 苯丙胺的非标准氨基酸结合物及其制备和使用的方法 - Google Patents

苯丙胺的非标准氨基酸结合物及其制备和使用的方法 Download PDF

Info

Publication number
CN101594778A
CN101594778A CNA2007800458802A CN200780045880A CN101594778A CN 101594778 A CN101594778 A CN 101594778A CN A2007800458802 A CNA2007800458802 A CN A2007800458802A CN 200780045880 A CN200780045880 A CN 200780045880A CN 101594778 A CN101594778 A CN 101594778A
Authority
CN
China
Prior art keywords
amphetamine
composition
amino acid
combination
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800458802A
Other languages
English (en)
Chinese (zh)
Inventor
特拉维斯·C.·米克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zevra Therapeutics Inc
Original Assignee
KemPharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KemPharm Inc filed Critical KemPharm Inc
Publication of CN101594778A publication Critical patent/CN101594778A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
CNA2007800458802A 2006-12-11 2007-12-10 苯丙胺的非标准氨基酸结合物及其制备和使用的方法 Pending CN101594778A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86937506P 2006-12-11 2006-12-11
US60/869,375 2006-12-11

Publications (1)

Publication Number Publication Date
CN101594778A true CN101594778A (zh) 2009-12-02

Family

ID=39512105

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800458802A Pending CN101594778A (zh) 2006-12-11 2007-12-10 苯丙胺的非标准氨基酸结合物及其制备和使用的方法

Country Status (11)

Country Link
US (3) US7776917B2 (enExample)
EP (1) EP2101571B1 (enExample)
JP (1) JP2010512413A (enExample)
CN (1) CN101594778A (enExample)
AT (1) ATE509622T1 (enExample)
AU (1) AU2007333105A1 (enExample)
BR (1) BRPI0720105A2 (enExample)
CA (1) CA2672138A1 (enExample)
ES (1) ES2364865T3 (enExample)
IL (1) IL198930A0 (enExample)
WO (1) WO2008073918A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111107878A (zh) * 2017-04-10 2020-05-05 夏尔制药公司 使用苯丙胺前药的治疗方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
EP2018160B1 (en) 2006-03-16 2011-12-14 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
EP2101571B1 (en) 2006-12-11 2011-05-18 Kempharm, Inc. Ornithine conjugates of amphetamine and processes for making and using the same
EP2433654A3 (en) 2007-02-08 2013-05-15 Kempharm, Inc. Citrulline and homocitrulline prodrugs of amphetamines and processes for making and using the same
DE102007037478B3 (de) 2007-08-08 2008-04-30 Leifheit Ag Wäschetrockenständer
US8614346B2 (en) 2009-06-19 2013-12-24 Cambrex Charles City, Inc. Methods and compositions for preparation of amphetamine conjugates and salts thereof
ES2710617T3 (es) 2010-04-21 2019-04-26 Signature Therapeutics Inc Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos
US8779191B2 (en) 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
CA3123900A1 (en) * 2011-07-28 2013-01-31 Kempharm Inc. Methylphenidate-prodrugs, processes of making and using the same
US20140171510A1 (en) * 2011-07-29 2014-06-19 Shire Llc Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014002039A1 (en) * 2012-06-27 2014-01-03 Shire Ag Amphetamine prodrugs
WO2014058742A1 (en) 2012-10-09 2014-04-17 Sears Douglas Therapeutic treatment
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
GB2556817B (en) 2015-10-01 2019-11-06 Elysium Therapeutics Inc Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
JP2020500220A (ja) 2016-11-15 2020-01-09 クラリア ファーマ ホールディング エービー 医薬製剤
CN110234636B (zh) 2016-12-11 2022-09-20 坎普哈姆公司 包含哌醋甲酯前药的组合物，其制造和使用方法
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTI-UNIT OPIOID MEDICINES RESISTANT TO OVERDOSE AND ABUSE
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
EP3692042A1 (en) * 2017-10-06 2020-08-12 Instituto de Medicina Molecular João Lobo Antunes Treatment of obesity-related conditions
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
WO2019199731A1 (en) * 2018-04-10 2019-10-17 Shire Pharmaceuticals Inc. Amphetamine prodrug and crystalline froms thereof
GB201808462D0 (en) * 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2020181000A1 (en) * 2019-03-06 2020-09-10 Ensysce Biosciences, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
AU2020402994A1 (en) 2019-12-11 2022-06-23 Inspirna, Inc. Methods of treating cancer
TW202309004A (zh) * 2021-08-24 2023-03-01 美商精神醫學公司 藉由使用受控和非受控中間體獲取ｍｄｍａ前驅藥之合成途徑
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL198169A (enExample) * 1954-06-28
US2881113A (en) 1957-01-29 1959-04-07 Ortho Pharma Corp Therapeutically active compositions containing amphetamines
US2892753A (en) * 1957-02-26 1959-06-30 Boehringer Sohn Ingelheim Central nervous system stimulant
DE1493824A1 (de) 1964-01-27 1969-05-22 Hoffmann La Roche Verfahren zur Herstellung von Aminocarbonsaeureamiden
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
AU6528400A (en) 1999-08-23 2001-03-19 David M. Ockert Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
EP1292307A2 (en) 2000-06-09 2003-03-19 The Regents of The University of California Method of treating pain using nalbuphine and opioid antagonists
US6417184B1 (en) 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
EP2319540A1 (en) * 2002-02-22 2011-05-11 Shire LLC Sustained release pharmaceutical compounds to prevent abuse of controlled substances
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
WO2004091499A2 (en) * 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
NZ544162A (en) 2003-05-29 2008-09-26 Shire Llc Abuse resistant amphetamine compounds
US20080234206A1 (en) 2005-09-13 2008-09-25 Shire Llc Prodrugs of Phentermine
EP2101571B1 (en) * 2006-12-11 2011-05-18 Kempharm, Inc. Ornithine conjugates of amphetamine and processes for making and using the same
EP2433654A3 (en) * 2007-02-08 2013-05-15 Kempharm, Inc. Citrulline and homocitrulline prodrugs of amphetamines and processes for making and using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111107878A (zh) * 2017-04-10 2020-05-05 夏尔制药公司 使用苯丙胺前药的治疗方法

Also Published As

Publication number Publication date
AU2007333105A1 (en) 2008-06-19
EP2101571B1 (en) 2011-05-18
US20080139653A1 (en) 2008-06-12
US20100292336A1 (en) 2010-11-18
BRPI0720105A2 (pt) 2014-10-07
ES2364865T3 (es) 2011-09-15
JP2010512413A (ja) 2010-04-22
US7776917B2 (en) 2010-08-17
EP2101571A4 (en) 2010-01-13
WO2008073918A1 (en) 2008-06-19
IL198930A0 (en) 2010-02-17
US20090234018A1 (en) 2009-09-17
ATE509622T1 (de) 2011-06-15
EP2101571A1 (en) 2009-09-23
US8101661B2 (en) 2012-01-24
HK1131518A1 (en) 2010-01-29
CA2672138A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
CN101594778A (zh) 苯丙胺的非标准氨基酸结合物及其制备和使用的方法
KR101159477B1 (ko) 남용 방지성 암페타민 화합물
EP2109465B1 (en) Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
US7169752B2 (en) Compounds and compositions for prevention of overdose of oxycodone
JP2009533443A (ja) 一置換及び二置換のオキシコドン化合物及び組成物
JP2014521641A (ja) ホモアルギニンプロドラッグおよび／またはアンフェタミンおよび他の興奮剤の抱合体、ならびに同物を作製および使用するためのプロセス
HK1131518B (en) Ornithine conjugates of amphetamine and processes for making and using the same
HK1088254B (en) Abuse resistant amphetamine compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091202